SF3B1 and myelodysplastic syndrome: Following MEDALIST, the COMMANDS study compared first‐line Luspatercept versus ESA in patients with lower‐risk MDS and red cell transfusion dependence, regardless of the presence of ring sideroblasts or SF3B1 mutations, meeting its primary endpoint, demonstrating superior achievement of transfusion independence (TI) in the Luspatercept versus ESA arm (59% v 31%) with a mean increase in hemoglobin of 1.5 g by 24 weeks (p < 0.0001).103